Results 1 to 10 of about 1,341 (183)

Efficacy of rezafungin in a case of Candida spondylodiskitis [PDF]

Journal of Bone and Joint Infection
Rezafungin, which only requires weekly administration, is a potential candidate for difficult-to-treat infections that require long-term antimicrobial treatment, such as bone and joint infections.
M. Lahouati, M. Lahouati, C. Tinévez, C. Tinévez, F. Gabriel, F. Xuereb, F. Xuereb, M. Lefranc, F.-A. Dauchy, F.-A. Dauchy   +9 more
doaj   +9 more sources

Rezafungin Utilisation in Real Life-FungiScope Results From Europe and the United States. [PDF]

Mycoses
Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC).
Reinhold I, Mori G, Lanzafame M, Limongelli A, Vena A, Götz J, Bauernfeind S, Hanses F, Tometten L, Mayer M, Rieke A, Soriano-Martin A, Valerio M, Vazquez JA, Yue P, Rahimli L, Azimli N, Sal E, Salmanton-García J, Vasenda N, Sprute R, Stemler J, Wingen-Heimann S, Cornely OA, Seidel D.   +24 more
europepmc   +4 more sources

It’s Here, It’s There, There’s Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis [PDF]

Infectious Diseases and Therapy
Rezafungin is a long-acting echinocandin with broad coverage against Candida. Rezafungin has primarily been indicated for candidemia, with limited literature available on its use for infections outside of the bloodstream.
Jacob M. Keck, Ryan K. Dare, Mitchell B. Jenkins, Juan C. Rico, Luke Grisham, Jennifer McDonald, Alina Viteri, Robert W. Bradsher   +7 more
doaj   +3 more sources

Activity of rezafungin against Candida auris. [PDF]

J Antimicrob Chemother
The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates of mortality ...
Locke JB, Andes D, Flanagan S, Redell M, Ong V, Aram JA, Pappas PG, Castanheira M, Thompson GR.   +8 more
europepmc   +4 more sources

Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double-Blind, Randomised, Phase 3 Trial (ReSTORE China). [PDF]

Mycoses
The global double‐blind, randomised, Phase 3 ReSTORE trial (NCT03667690) demonstrated noninferiority of rezafungin versus caspofungin for all‐cause mortality at Day 30 and global cure at Day 14 in patients with candidemia and/or invasive candidiasis.
Huang H, Feng S, Yu Y, Zhang Y, Yuan Y, Cox L, Zhang Y.   +6 more
europepmc   +3 more sources

Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria [PDF]

Journal of Clinical Microbiology
This study addresses the use of other echinocandins as surrogate markers to predict the susceptibility of rezafungin against the six most common Candida spp.
Marisa L. Winkler, Lalitagauri Deshpande, John H. Kimbrough, Maura Karr, Paul Rhomberg, Abby L. Klauer, Mariana Castanheira   +6 more
doaj   +3 more sources

Cost-Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom. [PDF]

Mycoses
ABSTRACT Background Invasive candidiasis (IC), life‐threatening fungal infections with high economic burden, are often treated first‐line with daily intravenous echinocandins. A new once weekly echinocandin, rezafungin, demonstrated statistically non‐inferior efficacy and numerically shorter intensive care unit (ICU) stay compared to caspofungin in ...
Muszbek N, Angdembe A, Garcia-Vidal C, Bielicka I, Abrams KR, Tolley K, Ruhnke M, Lebmeier M, Hawkins N, Manamley N, Dickerson S.   +10 more
europepmc   +2 more sources

Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice. [PDF]

Mycoses
ABSTRACT Background Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings.
Boán J, Aparicio-Minguijón E, Fernández-Ruiz M, Pérez-Jacoiste Asín MA, Rodríguez-Goncer I, López-Medrano F, San-Juan R, Silva JT, Pérez-Ayala A, Caro-Teller JM, Aguado JM.   +10 more
europepmc   +2 more sources

The Importance of Early Mycological Clearance of Uncomplicated Candidaemia and Its Implications for Clinical Practice. [PDF]

Mycoses
ABSTRACT Invasive candidiasis is a life‐threatening infection associated with high morbidity, mortality and healthcare costs in both general and critical care settings. Timely diagnosis and adequate antifungal treatment are essential to improving patient outcomes and limiting unnecessary use of healthcare resources.
Cornely OA, Bassetti M, Garcia-Vidal C, Hoenigl M, Maertens J, Martin-Loeches I, Mira JP, White PL.   +7 more
europepmc   +2 more sources

Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study. [PDF]

Open Forum Infect Dis
Background Rezafungin is approved for use in adults with candidemia and/or invasive candidiasis (IC) based on data from the ReSTORE trial (NCT03667690), which demonstrated noninferior efficacy to caspofungin. For regulatory purposes, an additional cohort
Thompson GR, Huang H, Feng S, Yu Y, Soriano A, Cornely OA, Kullberg BJ, Pappas PG, Kollef M, Vazquez JA, Honore PM, Cox L, Bassetti M.   +12 more
europepmc   +2 more sources